— Know what they know.
Not Investment Advice

DAWN NASDAQ

Day One Biopharmaceuticals, Inc.
1W: +0.3% 1M: +0.8% 3M: +80.2% YTD: +143.3% 1Y: +189.4% 3Y: +69.9%
$21.53
Last traded 2026-04-24 — delisted
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 60 · $2.2B mcap · 71M float · 5.62% daily turnover · Short 35% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$2.2B
52W Range5.635-21.53
Volume0
Avg Volume4,006,348
Beta-1.75
Dividend
Analyst Ratings
6 Buy 6 Hold 0 Sell
Consensus Buy
Company Info
CEOJeremy Bender
Employees181
SectorHealthcare
IndustryBiotechnology
IPO Date2021-05-27
395 Oyster Point Boulevard
Brisbane, CA 94080
US
650 484 0899
About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Recent Insider Trades

NameTypeSharesPriceDate
AI Day1 LLC U-Tender 12,929,322 $21.50 2026-04-23
Bender Jeremy D-Return 286,000 $8.99 2026-04-23
Bender Jeremy D-Return 355,000 $11.16 2026-04-23
Bender Jeremy D-Return 222,188 2026-04-23
VASCONCELLES MICHAEL D-Return 346,000 $6.64 2026-04-23

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms